Ex vivo cell therapy CMC input model
Ex vivo cell therapy programs involve the genetic or functional modification of cells outside the patient before reinfusion. Typical modalities include CAR-T, CAR-NK, TCR-T, gene-edited immune cell therapies, and other engineered cell therapy workflows. These programs depend on high-quality CMC inputs that support cell modification, transient expression, gene editing, vector-related workflows, process development, and regulatory documentation.
CATUG positioning
CATUG supports ex vivo cell therapy workflows by providing GMP-grade or GMP-oriented nucleic acid and protein materials, including plasmid DNA, mRNA/circRNA payloads, gRNA/sgRNA, gene-editing enzymes, reprogramming-related materials, targeting ligands such as nanobodies or antibody fragments, and selected functional protein reagents where applicable. Rather than positioning itself as a full cell-processing CDMO, CATUG focuses on the critical upstream and enabling components that help de-risk cell engineering workflows.
Key CMC priorities
From a CMC perspective, key priorities include material quality, batch consistency, impurity control, expression performance, documentation readiness, scalability of critical inputs, and compatibility with downstream cell-processing requirements.
CATUG integrated support
CATUG’s integrated capabilities in plasmid DNA, RNA drug substance, protein/nanobody production, analytical development, GMP-oriented manufacturing, and CMC documentation help clients move from early feasibility to IIT, IND-enabling, and clinical-stage programs.
Flexible entry points
Support can be tailored to different entry points, including research-grade feasibility materials, GMP-grade plasmid or RNA supply, guide RNA and gene-editing material support, protein or nanobody reagents, analytical testing, release documentation, and CMC source documents for regulatory packages.
Stem cell and iPSC enabling-material model
Stem cell therapy and iPSC-based programs require high-quality enabling materials for reprogramming, differentiation, transient expression, gene editing, cell-line engineering, and process development. These materials are often needed in small quantities but must still meet defined quality, consistency, and documentation requirements, as they can directly affect downstream cell identity, process robustness, reproducibility, and clinical translation.
CATUG integrated support
CATUG supports stem cell and iPSC-related workflows through plasmid DNA, mRNA/circRNA payloads, gRNA/sgRNA, gene-editing enzymes, reprogramming-related plasmid/RNA/protein materials, targeting ligands, selected cytokines or growth factors, analytical support, GMP-oriented manufacturing, and CMC documentation. For reprogramming or transient expression workflows, non-integrating nucleic acid or protein-based approaches may help reduce genomic integration concerns and support more controllable process development strategies.
Flexible small-quantity supply
Because many iPSC and stem-cell-related programs require low-volume, multi-material, and cost-sensitive supply, CATUG can provide flexible, small-quantity, stage-appropriate solutions rather than forcing clients into oversized manufacturing packages. Depending on project needs, we can support research-grade, GMP-like, or GMP-oriented materials with fit-for-purpose analytics and documentation, helping clients balance quality, speed, and COGS from early feasibility through process development.
Key CMC priorities
From a CMC perspective, key challenges include reagent quality, expression efficiency, residual impurity control, batch-to-batch consistency, traceability, scale-up readiness, and alignment with downstream stem-cell processing requirements. CATUG helps clients evaluate and manufacture critical CMC inputs under stage-appropriate quality frameworks, supporting early feasibility, process development, IIT, IND-enabling, and clinical-stage preparation where applicable.
Why CATUG for stem cell and iPSC programs
CATUG’s role is to support the enabling materials and CMC workflows behind stem cell therapy development, rather than to overstate a one-size-fits-all stem cell manufacturing solution. Through integrated plasmid, RNA, protein/nanobody, analytical, GMP-oriented manufacturing, and documentation capabilities, CATUG helps developers build more controlled, flexible, and economically viable paths for advanced cell therapy programs.
CATUG supports ex vivo cell therapy, stem cell, and iPSC-related programs by providing critical upstream CMC inputs, including plasmid DNA, RNA payloads, guide RNA, gene-editing materials, LNP materials, protein / nanobody reagents, analytical support, GMP-oriented manufacturing, and documentation. For ex vivo CAR-related programs, CATUG has project experience supporting both China and U.S. IND filings.
CATUG does not position itself as a full cell-processing CDMO. The focus is on high-quality, stage-appropriate materials and CMC inputs that enable cell engineering, reprogramming, transient expression, gene editing, LNP-enabled cell transfection, and downstream process development.
Supports CAR-T, CAR-NK, TCR-T, gene-edited immune cell therapy, and other engineered cell therapy workflows through flexible upstream nucleic acid, editing, LNP, and protein materials.
Supports reprogramming, differentiation, transient expression, gene editing, and iPSC-related process development through flexible, small-quantity, multi-material supply.
Designed for route-flexible, multi-material, low-volume, quality-controlled enabling material supply.
Plasmid-only, plasmid + RNA, or plasmid + RNA + LNP input strategies.
Flexible supply for feasibility, process development, and early-stage programs.
Project experience supporting China and U.S. IND filings for ex vivo CAR-related programs.
Avoids forcing early programs into oversized manufacturing packages too early.
CATUG connects plasmid, RNA, LNP, gene-editing, protein, nanobody, analytical, and documentation capabilities to support different cell engineering routes and enabling material needs behind ex vivo cell therapy, stem cell, and iPSC programs.
Supports different ex vivo cell engineering strategies, including plasmid-only supply, plasmid + RNA inputs for electroporation, and plasmid + RNA + LNP workflows for cell transfection or delivery feasibility studies.
Plasmid construction, supercoiled plasmid manufacturing, linearized IVT template preparation, mRNA / circRNA payload manufacturing, and RNA DS support for transient expression, gene editing, and cell engineering workflows.
Guide RNA, sgRNA-related workflows, donor-template-related support, gene-editing enzyme materials, and compatibility considerations for electroporation or LNP-enabled cell engineering workflows.
Selected functional proteins, enzymes, reprogramming-related materials, cytokines, growth factors, and protein reagents for early feasibility and process development.
Nanobody, antibody fragment, peptide, or other ligand-related material support for targeted delivery, immune-cell targeting, LNP-enabled cell engineering, and advanced therapy feasibility studies.
Analytical testing, identity and purity support, impurity control, CoA, batch records, release documentation, CMC source documents, and project experience supporting China and U.S. IND filings for ex vivo CAR-related programs.
CATUG supports cell therapy and stem-cell-related programs through flexible entry points, from research-grade feasibility materials to GMP-oriented inputs and CMC documentation for IIT, IND-enabling, and clinical-stage preparation.
Built for CAR-T, CAR-NK, TCR-T, and gene-edited immune cell programs where clients may need plasmid-only inputs, plasmid + RNA for electroporation, or plasmid + RNA + LNP materials for cell transfection, delivery feasibility, and IND filing-ready CMC input documentation. CATUG has supported ex vivo CAR-related projects for both China and U.S. IND filings.
Built for iPSC, stem cell, reprogramming, differentiation, transient expression, and cell-line engineering workflows requiring flexible small-quantity materials and stage-appropriate quality control.